Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: MOTS-c + SS-31 evidence and protocol review
Also known as: MOTS/SS31
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
MOTS-c + SS-31 combines MOTS-c + SS-31 into a single research protocol. Each component is independently studied; this entry summarizes the individual evidence base for the combination, since no unified safety/efficacy dataset covers the mixed formulation unless noted below. MOTS-c: Mitochondrial-derived peptide (12S rRNA-encoded) studied for AMPK-linked metabolic regulation and exercise-mimetic effects; preclinical biology well-characterized, zero completed human interventional trials as of 2026. SS-31: Cardiolipin-targeted mitochondrial peptide; FDA-granted accelerated approval (Sept. 2025) as Forzinity (elamipretide) - the first FDA-approved mitochondria-targeted therapeutic - for muscle strength in Barth syndrome. This is a community-stacking combination assembled from two independently studied compounds rather than a pharmaceutical sponsor's dedicated fixed-dose combination program - no dedicated human combination trial exists for this exact pairing as of this writing.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence for individual components does not validate the exact mixed formulation. Component amounts, ratios, compatibility, sterility, and stability must be documented.
Supplementary research context only. Not medical advice or a treatment recommendation.
Best-effort summary of forum/Reddit discussion. This is anecdotal community commentary, not a scientific source, and does not count toward this record's verification status. Do not treat it as established fact or medical guidance.
Community dosing guides separately describe MOTS-c (5-10 mg weekly, mitochondrial/metabolic support, 'still experimental') and SS-31/Elamipretide (1-10 mg/day sub-Q) as 'highly regarded in longevity circles' for mitochondrial protection and cellular health -- among the more favorably-discussed compounds in this category. The combined MOTS-c+SS-31 stack itself wasn't found discussed as a named blend. Anecdotal only.
undefined
Community tier-list ranking of mitochondrial/metabolic peptides including MOTS-c and SS-31, based on user-reported experiences; crowd-sourced opinion, not clinically verified.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention MOTS-c + SS-31 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.